Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 to Distribute DeCode Tests in UK, Ireland

NEW YORK – (GenomeWeb News) – Lab21 said today that it will offer five of DeCode Genetics’ tests in the UK and in Ireland, and it will have the rights to offer new tests that are not yet on the market.
 
The agreement allows the Cambridge, UK-based Lab21 to offer DeCode’s tests for type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer, and glaucoma, as well as an upcoming test for the risk of estrogen-positive breast cancer and “a pipeline” of other tests DeCode has in development. 
 
Lab21 also offers tests from Myriad Genetics and PGxHealth, including tests for various cancers and for cardiovascular disease. The company said that all the DeCode tests it has agreed to market have “full regulatory approval.”
 
Financial terms of the agreement were not released.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.